Halozyme Therapeutics (NASDAQ: HALO) net income
Halozyme Therapeutics reported a net profit of $316.9m for fiscal 2025, 28.6% less than in fiscal 2024 ($444.1m). Its net margin was 22.7%. Earnings per share were $2.64.
Halozyme Therapeutics's best year of the last 10 was fiscal 2024. The biggest drop was in fiscal 2022, −49.8%. It reported a loss in 3 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $316.9m | −28.6% | 22.7% | $2.64 |
| 2024 | $444.1m | +57.7% | 43.7% | $3.50 |
| 2023 | $281.6m | +39.3% | 34.0% | $2.13 |
| 2022 | $202.1m | −49.8% | 30.6% | $1.48 |
| 2021 | $402.7m | +212.0% | 90.8% | $2.86 |
| 2020 | $129.1m | — | 48.2% | $0.95 |
| 2019 | −$72.2m | — | −36.9% | −$0.50 |
| 2018 | −$80.3m | −227.6% | −52.9% | −$0.56 |
| 2017 | $63.0m | — | 19.9% | $0.46 |
| 2016 | −$103.0m | — | −70.2% | −$0.81 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Halozyme Therapeutics net income compared with its sector
By net income for its latest fiscal year, Halozyme Therapeutics ranks 73rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Halozyme Therapeutics, 22.7%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 71st | BioMarin Pharmaceutical | $348.9m | 10.8% |
| 72nd | Ensign Group | $344.0m | 6.8% |
| 73rd | Halozyme Therapeutics | $316.9m | 22.7% |
| 74th | Alnylam Pharmaceuticals | $313.7m | 8.4% |
| 75th | Aurinia Pharmaceuticals | $287.2m | 101.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Halozyme Therapeutics
- How much did Halozyme Therapeutics earn in fiscal 2025?
- Halozyme Therapeutics reported a net profit of $316.9m for fiscal 2025. In fiscal 2024 it reported a net profit of $444.1m.
- What are the earnings per share of Halozyme Therapeutics?
- They were $2.64 in fiscal 2025, compared with $3.50 in fiscal 2024.
- What is the net margin of Halozyme Therapeutics?
- In fiscal 2025 its net profit was 22.7% of its revenue.
- What was the most profitable year for Halozyme Therapeutics?
- Of its last 10 fiscal years, fiscal 2024, with $444.1m.
- Where does Halozyme Therapeutics rank in its sector by net income?
- It ranks 73rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Halozyme Therapeutics come from?
- From the annual report (Form 10-K) that Halozyme Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Halozyme Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Halozyme Therapeutics: the Halozyme Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.